Combining the higher expression levels of TAZ and BID in this group, we speculate that high-risk ccRCC patients are more sensitive to ferroptosis and targeting ferroptosis to treat such patients may have a better therapeutic effect. Here, BID is linked to nonpapillary renal cell carcinoma.